Clorox Employees Share Their Stories for National Infertility Awareness Week
NORTHAMPTON, MA / ACCESSWIRE / April 26, 2024 / About one in six adults worldwide experience fertility issues, including 9% of men and 11% of women of reproductive age in the U.S., according to the World Health Organization.
To better understand the diverse issues that can cause someone to seek fertility treatment, some of our Clorox teammates shared their experiences. They're telling their stories during National Infertility Awareness Week to help others who may be facing similar challenges.
The Clorox Company is dedicated to creating a culture that values and prioritizes the health and well-being of our teammates. Our benefits, programs, and resources are designed to support physical, mental and financial well-being. Learn more about life at Clorox here.
View additional multimedia and more ESG storytelling from The Clorox Company on 3blmedia.com.
Contact Info:
Spokesperson: The Clorox Company
Website: https://www.3blmedia.com/profiles/clorox-company
Email: info@3blmedia.com
SOURCE: The Clorox Company
View the original press release on accesswire.com
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?